RecruitingNot ApplicableNCT07234968

Clinical Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy

Randomized Controlled Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy


Sponsor

Thomas Jefferson University

Enrollment

70 participants

Start Date

Dec 23, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Subjects will be randomized into 2 groups (stent or no stent) prior to radical cystectomy with ileal conduit urinary diversion (RCIC). They will follow the standard of care and be enrolled in the study for 12 months post-op. Risk of post-op complications will be analyzed.


Eligibility

Min Age: 18 YearsMax Age: 85 Years

Inclusion Criteria4

  • Provide signed and dated informed consent form
  • Willing to comply with all study procedures and be available for the duration of the study
  • Male or female, age 18 to 85
  • Diagnosed with bladder cancer, other pelvic malignancies necessitating a cystectomy (e.g.: colorectal, prostate, gynecologic) and have elected for a cystectomy with ileal conduit urinary diversion

Exclusion Criteria5

  • An individual who meets any of the following criteria will be excluded from participation in this study:
  • Current or history of pelvic radiation
  • Retroperitoneal fibrosis
  • Untreated urinary tract infection (UTI) within 30 days prior to RCIC
  • Pregnancy

Interventions

PROCEDUREUreteral Stent Placement

Placement of ureteral stents (double J or single J) intraoperatively during radical cystectomy with ileal conduit urinary diversion (RCIC). Stent placement will be a one-time occurrence inserted during RCIC, and be removed typically between 7-21 days post-op at the discretion of the surgeon.

PROCEDURENo Ureteral Stent

Radical cystectomy with ileal conduit urinary diversion (RCIC) performed without ureteral stent placement.

DIAGNOSTIC_TESTIndocyanine Green with Fluorescence Imaging

Indocyanine green (ICG) with fluorescence imaging is an advanced technique used to enhance the visualization of the ureters during complex pelvic surgeries, such as those for bladder cancer. The technology helps surgeons identify the ureters, which are the tubes connecting the kidneys to the bladder, and distinguish them from surrounding tissues.


Locations(2)

Thomas Jefferson University Hospital

Philadelphia, Pennsylvania, United States

Jefferson Einstein Philadelphia Hospital

Philadelphia, Pennsylvania, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07234968


Related Trials